The latest advances in breast cancer vaccines are focused on the development of a preventive vaccine against triple-negative breast cancer. Triple-negative breast cancer is defined as a disease that is negative for estrogen, progesterone receptors, and epidermal growth factor receptors, and thus triple-negative breast cancer does not respond to sex hormones or targeted therapies, and patients with this disease account for a large percentage of breast cancer deaths. Recently, a Phase 1 trial of a vaccine designed to prevent the development of triple-negative breast cancer is underway, and the study will determine the maximum tolerated dose of the vaccine in patients and determine and optimize the body’s immune response to the vaccine. The ability of the triple-negative breast cancer prevention vaccine to activate the innate immune response and prevent tumor growth represents a potentially effective new approach to controlling breast cancer. In addition, this triple-negative breast cancer prevention vaccine could potentially be applied to other types of tumors in the future to prevent diseases faced as we age, such as breast, ovarian and endometrial cancers. Such vaccines, once developed, will improve the quality of women’s lives, and administering this new vaccine to healthy women will prevent them from developing triple-negative breast cancer, which would be an effective form of breast cancer treatment. If you have breast cancer, it is recommended that you visit a hospital and follow your doctor’s instructions.